John Strickler

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2005

University of Chicago

Residency, Medicine

University of Washington

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

Nektar

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

AbbVie M14-064

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

AbbVie M16-438

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Seattle Genetics-SGN2FF001: A Phase 1, multicenter, open-label, dose-escalation study

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

A Multicenter, phase I open-label dose escalation study of ABBV-085 an antibody drug conjugated in subjects with advanced solid tumors.

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.

Authors
Jia, J; Niedzwiecki, D; Uronis, HE; Morse, M; Zafar, Y; Hsu, SD; Bolch, E; Nagy, RJ; Lanman, RB; Talasaz, A; Haley, S; Nixon, AB; Strickler, JH
MLA Citation
Jia, Jingquan, et al. “A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood..” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 3555–3555. Crossref, doi:10.1200/jco.2018.36.15_suppl.3555.
URI
https://scholars.duke.edu/individual/pub1351168
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
36
Published Date
Start Page
3555
End Page
3555
DOI
10.1200/jco.2018.36.15_suppl.3555

Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)

Authors
Bendell, J; Eckhardt, GS; Hochster, HS; Morris, VK; Strickler, J; Kapoun, AM; Wang, M; Xu, L; McGuire, K; Dupont, J; Faoro, L; Munster, P
MLA Citation
Bendell, J., et al. “Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC).” European Journal of Cancer, vol. 69, Elsevier BV, 2016, pp. S29–30. Crossref, doi:10.1016/s0959-8049(16)32668-5.
URI
https://scholars.duke.edu/individual/pub1169111
Source
crossref
Published In
European Journal of Cancer
Volume
69
Published Date
Start Page
S29
End Page
S30
DOI
10.1016/s0959-8049(16)32668-5

Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).

Authors
Kang, Y-K; LoRusso, P; Salgia, R; Yen, C-J; Lin, C-C; Ramanathan, RK; Kaminker, P; Sokolova, I; Bhathena, A; Wang, L; Naumovski, L; Strickler, JH
MLA Citation
Kang, Yoon-Koo, et al. “Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC)..” Journal of Clinical Oncology, vol. 33, no. 3_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 167–167. Crossref, doi:10.1200/jco.2015.33.3_suppl.167.
URI
https://scholars.duke.edu/individual/pub1170238
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
33
Published Date
Start Page
167
End Page
167
DOI
10.1200/jco.2015.33.3_suppl.167

Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.

Since its approval for the first-line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become a standard treatment option in combination with chemotherapy for patients with mCRC. Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab-based treatment regimens, its use in various patient populations, and the identification of associated adverse events. This review discusses the results of several phase II and phase III clinical trials, as well as large observational studies, to address the use of bevacizumab in the treatment of patients with mCRC in the first-line setting.
Authors
Strickler, JH; Hurwitz, HI
MLA Citation
Strickler, John H., and Herbert I. Hurwitz. “Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer..” Oncologist, vol. 17, no. 4, 2012, pp. 513–24. Pubmed, doi:10.1634/theoncologist.2012-0003.
URI
https://scholars.duke.edu/individual/pub777785
PMID
22477726
Source
pubmed
Published In
Oncologist
Volume
17
Published Date
Start Page
513
End Page
524
DOI
10.1634/theoncologist.2012-0003

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.

BACKGROUND: Veliparib is a potent poly(ADP-ribose) polymerase inhibitor. This phase 1 study aimed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of veliparib combined with various FOLFIRI regimens in patients with solid tumours. METHODS: Patients received veliparib (10-270 mg BID, days 1-5, 15-19) and FOLFIRI (days 1-3, 15-17) in three regimens containing 5-fluorouracil 2,400 mg/m2: irinotecan 150 mg/m2 and folinic acid 400 mg/m2 (part 1); irinotecan 180 mg/m2, folinic acid 400 mg/m2, and 5-fluorouracil 400 mg/m2 bolus (part 2), or irinotecan 180 mg/m2 (part 3). The RP2D was further evaluated in safety expansion cohorts. Preliminary antitumour activity was also assessed. RESULTS: Ninety-two patients received ≥1 veliparib dose. MTD was not reached; RP2D was set at 200 mg BID veliparib plus FOLFIRI (without 5-fluorouracil bolus). Most common treatment-emergent adverse events were neutropenia (66.3%), diarrhoea, and nausea (60.9% each). Dose-limiting toxicities (n = 4) were grade 3 gastritis and grade 4 neutropenia and febrile neutropenia. Veliparib exposure was dose-proportional, with no effects on the pharmacokinetics of FOLFIRI components. Fifteen patients had a partial response (objective response rate, 17.6%). CONCLUSIONS: The acceptable safety profile and preliminary antitumour activity of veliparib plus FOLFIRI support further evaluation of this combination.
Authors
Berlin, J; Ramanathan, RK; Strickler, JH; Subramaniam, DS; Marshall, J; Kang, Y-K; Hetman, R; Dudley, MW; Zeng, J; Nickner, C; Xiong, H; Komarnitsky, P; Shepherd, SP; Hurwitz, H; Lenz, H-J
MLA Citation
Berlin, Jordan, et al. “A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours..” Br J Cancer, vol. 118, no. 7, 2018, pp. 938–46. Pubmed, doi:10.1038/s41416-018-0003-3.
URI
https://scholars.duke.edu/individual/pub1170237
PMID
29527010
Source
pubmed
Published In
Br J Cancer
Volume
118
Published Date
Start Page
938
End Page
946
DOI
10.1038/s41416-018-0003-3